Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347122 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
A Phase 4 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT04347122: Clinical Trial Phase 4 study, sponsored by University of Kansas Medical Center.
NCT04347122 is a Phase 4 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 12 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04347122, a Phase 4 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
Primary Outcome
How much blood was lost during surgical process
Interventions
- DRUG Tranexamic Acid (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 4 |
Why NCT04347122 stopped before completion
NCT04347122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Tranexamic Acid (TXA) is the first listed.
NCT04347122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04347122 about?
NCT04347122 is a clinical study titled "Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction". This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
What is the current status of trial NCT04347122?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2020-01-28. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT04347122?
The interventions under investigation include: Tranexamic Acid (TXA) (DRUG).
Who is sponsoring clinical trial NCT04347122?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04347122's enrollment target sits among peer trials
12 1913th of 2000 higher than 70 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI